Vox Markets Logo

Diurnal Group receives validation for hormonal drug Chronocort® 

10:03, 1st April 2020
Francesca Morgan
RNS Newswire
TwitterFacebookLinkedIn

London-listed Diurnal Group (AIM: DNL FOLLOW) announced on Wednesday that it had received validation by the European Marketing Authorisation for its Chronocort® product which treats a rare genetic disorder. 
 
The UK-based pharmaceutical company, which focuses on treatments for hormonal diseases, said that a formal review process of its hormonal drug product, Chronocort®, can now begin. 
 
The group said it is in “a strong cash position” to progress through to the anticipated approval date for Chronocort® following its recent $52.5m US licensing agreement for its Alkindi® Sprinkle product and a £11.2m placing. 
 
Diurnal filed for authorisation in December following an earlier confirmation of a clinical and regulatory pathway for Chronocort® as a treatment for congenital adrenal hyperplasia (CAH). 
 
Shares in Diurnal Group were trading flat at 30.5p during Wednesday trading. 

DNL price chart

CAH results in low levels of cortisol and high levels of male hormones in the body, causing the development of male characteristics in females, and early puberty in both boys and girls. 
 
The group has recognised the need for therapies for adults living with CAH which is estimated to affect over 441,000 patients globally and results in “increased morbidity and mortality.” 
 
Whitaker further acknowledged the validation as “another important step” towards the targeted recommendation for the approval of a second product in the first quarter of 2021. 
 
In a previous statement, the group also said it would continue to assess “the optimum path and timing” to develop and commercialise Chronocort® in the US. 
 
Follow news & Updates from Diurnal Group here: FOLLOW

TwitterFacebookLinkedIn

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Recent Articles
Watchlist